Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 7,248 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Anxiety Disorders
Interventions: Gabitril; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 86
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 73 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 20 Years to 74 Years
Enrollment: 2,378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • Iowa City, Iowa • Detroit, Michigan + 1 more

Conditions: Coronary Artery Disease (CAD), Coronary Calcification, Coronary Calcified Disease, Coronary Calcified Nodules
Interventions: Shockwave C2 Aero Coronary IVL System; Device
Lead sponsor: OPCI Core Laboratories LLC; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 8
States / cities: Thousand Oaks, California • Detroit, Michigan • Neptune City, New Jersey + 5 more

Conditions: Chronic Hepatitis B
Interventions: Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Hematologic Malignancy
Interventions: Age 60+ with planned HCT for Hematologic Malignancy; Diagnostic Test
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 60 Years and older
Enrollment: 1,229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 50
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 41 more

Conditions: Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIC Ovarian Germ Cell Tumor, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma
Interventions: conventional surgery, cisplatin, etoposide, bleomycin sulfate, laboratory biomarker analysis; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 112
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 98 more

Conditions: Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Interventions: Thor laser atherectomy; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: St. Helena, California • Aurora, Colorado • Bradenton, Florida + 24 more

Conditions: Epilepsy, Partial
Interventions: Levetiracetam, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more

Conditions: Non-Alcoholic Steatohepatitis
Interventions: EDP-305 1.5 mg, EDP-305 2 mg, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 68
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 57 more

Conditions: Heart Failure
Interventions: Placebo, Omecamtiv mecarbil; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more

Conditions: Acne Vulgaris
Interventions: SB204 2%, SB204 4%, Vehicle Gel; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Hot Springs, Arkansas • Encinitas, California • San Diego, California + 15 more

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Rivaroxaban, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 38 more

Conditions: Transcatheter Aortic Valve Replacement
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 31
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin detemir, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 28
States / cities: Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more

Conditions: Acquired Hemophilia A
Interventions: OBIZUR; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 13 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: cytarabine, daunorubicin hydrochloride, midostaurin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 1 more

Conditions: Carcinoma, Renal Cell
Interventions: Bay 59-8862; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 13
States / cities: La Jolla, California • Muncie, Indiana • New Orleans, Louisiana + 9 more

Conditions: Asthma, Health Personnel
Interventions: ABIM asthma practice improvement module; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Stroke, Cerebral Ischemia, Brain Infarction
Interventions: Ancrod (Viprinex), Placebo; Drug
Lead sponsor: Neurobiological Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 58
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Loma Linda, California + 48 more

Conditions: Severe Acne Vulgaris
Interventions: Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 28
States / cities: Oceanside, California • San Diego, California • Denver, Colorado + 25 more

Conditions: Sleep Apnea, Age
Interventions: 1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Head and Neck Cancer
Interventions: cisplatin, paclitaxel, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 21 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 215
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Conditions: Postmenopausal Women With Osteoporosis
Interventions: Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 4,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.

Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma

AERO CAD Study Evaluating the Shockwave C2 Aero IVL System in Coronary Artery Disease

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

The THOR IDE Study

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Changes in Physician Performance Through Continuous Professional Development

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep

Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis